View Older Stories View More Recent Stories
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Ascendis Pharma (ASND) Submits U.S. NDA for TransCon CNP for the Treatment of Children with Achondroplasia
-
UBS Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Ascendis Pharma (ASND) PT Raised to $200 at Cantor Fitzgerald
-
Ascendis Pharma (ASND) PT Raised to $260 at Evercore ISI, Top Pick
-
Biotech Q4 earnings preview: Goldman Sachs
-
Ascendis Pharma (ASND) PT Raised to $162 at TD Cowen; 'Yorvipath Off to Solid Launch'
-
Ascendis Pharma (ASND) PT Raised to $212 at Stifel
-
Ascendis Pharma (ASND) PT Raised to $225 at Goldman Sachs
-
Ascendis Pharma (ASND) announces $25 million share repurchase program
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) PT Raised to $167 at JPMorgan
-
Goldman Sachs Reiterates Buy Rating on Ascendis Pharma (ASND)
-
BioMarin Pharma (BMRN) Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
-
UBS Starts Ascendis Pharma (ASND) at Buy
-
Ascendis Pharma (ASND) PT Raised to $194 at Jefferies
-
Ascendis Pharma (ASND): FDA Accepts SBLA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency
-
Ascendis Pharma (ASND) Selects PANTHERx Rare for the Distribution of YORVIPATH® (palopegteriparatide)
-
Ascendis Pharma (ASND) PT Lowered to $153 at TD Cowen
-
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
-
Ascendis Pharma (ASND) PT Lowered to $180 at Oppenheimer
-
Ascendis Pharma (ASND) Misses Q3 EPS by 18c, provides outlook
-
Ascendis Pharma (ASND) and Novo Nordisk (NVO) Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
-
Ascendis Pharma (ASND) PT Raised to $160 at TD Cowen
-
Ascendis Pharma (ASND) Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
-
Ascendis Pharma (ASND): New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
-
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) Prices 2M Share Offering at $150/sh
-
Ascendis Pharma (ASND) Announces Proposed Public Offering of ADSs
-
Ascendis Pharma (ASND) Files Mixed Shelf
-
Ascendis Pharma (ASND) PT Raised to $190 at Oppenheimer
-
Ascendis Pharma (ASND) PT Raised to $205 at Evercore ISI
-
Ascendis Pharma (ASND) PT Raised to $179 at Jefferies
-
Barclays Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Ascendis Pharma (ASND) option IV flat as share price up 19.8%
-
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
-
Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
-
Stifel on Ascendis Pharma (ASND): 'A Clear Win Following Recent Commercial Setbacks'
-
BioMarin Pharma (BMRN) Weakness Tied to Data From Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) Reports Pivotal ApproaCH Trial of TransCon CNP Achieved Primary Objective
-
Citi Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Ascendis Pharma (ASND) to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO
-
Citi Opens 30-Day Upside Catalyst Watch on Ascendis Pharma (ASND)
-
TD Cowen Reiterates Buy Rating on Ascendis Pharma (ASND)
-
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
-
Ascendis Pharma (ASND) PT Lowered to $157 at TD Cowen
-
Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)
-
Ascendis Pharma (ASND) PT Lowered to $174 at Jefferies
